Glycopyrrolate/indacaterol

Drug Profile

Glycopyrrolate/indacaterol

Alternative Names: Indacaterol maleate/glycopyrronium bromide; Indacaterol/glycopyrrolate; Indacaterol/NVA-237; NVA-237/indacaterol; NVA-237/QAB-149; QVA-149; Ultibro Breezhaler; Ultibro Inhalation Capsules; Ulunar Breezhaler; Utibron Neohaler; Xoterna Breezhaler

Latest Information Update: 06 Apr 2017

Price : $50

At a glance

  • Originator Arakis Ltd; Novartis; Vectura
  • Developer Novartis; Pfizer; Sunovion Pharmaceuticals
  • Class Antiasthmatics; Antispasmodics; Bronchodilators; Indans; Pyrrolidines; Quaternary ammonium compounds; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Chronic obstructive pulmonary disease

Most Recent Events

  • 03 Apr 2017 Launched for Chronic obstructive pulmonary disease in USA (Inhalation)
  • 03 Apr 2017 The approved label for glycopyrrolate/indacaterol has a black box warning
  • 03 Apr 2017 Adverse events data from two clinical trials in Chronic obstructive pulmonary disease released by Sunovion
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top